← Back to all signals
VRTX · Q3 2026

VERTEX PHARMACEUTICALS INC / MA

Reported 2026-08-03
BEAT
51EarnIQ signal
↗

Confidence rising

Mild quarter-over-quarter shift

Solid revenue growth, successful non-CF product launches, and upwardly revised guidance signal robust core business health.

  • ✓Guidance was raised, with high specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Headline confirmed

Management confidence reinforces the reported beat.

EPS: reported vs expected-1.9%$4.73 vs $4.82
Revenue: reported vs expected+1.1%$3.3B vs $3.3B
Guidance specificityHighRaised
Market expectations supplied by Finnhub · Reported vs consensus estimate

Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain.

✦
EarnIQ Premium

Understand exactly why confidence changed.

Unlock management-language evidence, guidance specificity, the pressure point, narrative breaks, risks, and quarter-over-quarter topic changes.

Guidance specificityPressure pointNarrative breakSource evidence
Preview full report